EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia

Tadao Akizawa iD, Natsuki Urano iD, Kazuaki Ikejiri iD, Kaoru Nakanishi iD, Masafumi Fukagawa iD

Therapeutic Apheresis and Dialysis · 2025-04 · 29 (2) · 157-169

DOI: 10.1111/1744-9987.14241 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 19.01.2025. Verfasst von Tadao Akizawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hyperphosphatemia, Renal Dialysis, Sulfonamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients on dialysis often develop hyperphosphatemia, contributing to an increased risk of cardiovascular events and mortality. Currently, several types of phosphate binders (PBs) exist for the treatment of hyperphosphatemia, but they are sometimes associated with drug‐specific side effects and high pill burden, making it difficult to control serum phosphorus appropriately. Tenapanor, which has a novel mechanism to reduce serum phosphorus via selective sodium/proton exchange transporter 3 inhibition, was approved for hyperphosphatemia in Japan in 2023. Four phase 3 studies of tenapanor have been performed in Japan and have demonstrated its efficacy and safety as a single‐agent drug, add‐on effects to PBs for patients with refractory hyperphosphatemia that cannot be improved with PBs alone, and reduction of the pill burden associated with PBs. This review provides an overview of the characteristics and previous clinical studies of tenapanor and describes the clinical benefits of tenapanor over current therapy in patients on dialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaRenal DialysisSulfonamidesHumansJapanChelating AgentsIsoquinolines

Stichwörter der Autor:innen

NHE3 inhibitordialysis patientshyperphosphatemiaintestinal phosphate absorption inhibitortenapanor

Substanzen

tenapanorSulfonamidesChelating AgentsIsoquinolines

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Development Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
  • Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

ORCID-Profile: Tadao Akizawa, Natsuki Urano, Kazuaki Ikejiri, Kaoru Nakanishi, Masafumi Fukagawa

Förderung

  • Kyowa Kirin

Zitieren

APA

Akizawa, T., Urano, N., Ikejiri, K., Nakanishi, K., & Fukagawa, M. (2025). Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia. Therapeutic Apheresis and Dialysis, 29(2), 157-169. https://doi.org/10.1111/1744-9987.14241

Vancouver

Akizawa T, Urano N, Ikejiri K, Nakanishi K, Fukagawa M. Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia. Therapeutic Apheresis and Dialysis. 2025;29(2):157-169. doi:10.1111/1744-9987.14241

BibTeX
@article{Akizawa2025,
  author = {Akizawa, Tadao and Urano, Natsuki and Ikejiri, Kazuaki and Nakanishi, Kaoru and Fukagawa, Masafumi},
  title = {Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2025},
  volume = {29},
  number = {2},
  pages = {157--169},
  doi = {10.1111/1744-9987.14241}
}
Kostenlos starten →